Correction: SGLT2-inhibitors in diabetic patients with severe aortic stenosis and cardiac damage undergoing transcatheter aortic valve implantation (TAVI)
Correction: SGLT2-inhibitors in diabetic patients with severe aortic stenosis and cardiac damage undergoing transcatheter aortic valve implantation (TAVI)
(2025)
Correction: SGLT2-inhibitors in diabetic patients with severe aortic stenosis and cardiac damage undergoing transcatheter aortic valve implantation (TAVI)
Year:
2025
Type of item:
Articolo in Rivista
Tipologia ANVUR:
Articolo su rivista
Language:
Inglese
Referee:
No
Name of journal:
CARDIOVASCULAR DIABETOLOGY
ISSN of journal:
1475-2840
N° Volume:
24
Number or Folder:
1
Page numbers:
1-14
Keyword:
aortic stenosis
Short description of contents:
Background A substantial number of patients with severe aortic stenosis (AS) undergoing transcatheter aortic
valve implantation (TAVI) experience adverse events after TAVI, with health care expenditure. We aimed to investigate
cardiac remodeling and long-term outcomes in diabetic patients with severe AS, left ventricular ejection fraction
(LVEF) < 50%, and extra-valvular cardiac damage (EVCD) undergoing TAVI treated with sodium-glucose cotransporter-2 inhibitors (SGLT2i) versus other glucose-lowering strategies (no-SGLT2i users).